Statistics

Total Visits

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials97

Select a period of time:

Number of views in the range

Views
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials24

Views

Views
May 20253
June 20251
July 202515
August 20250
September 20252
October 20251
November 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States12
Brazil10
Ecuador1
United Kingdom1
 

Top cities views

Views
Rio de Janeiro2
Council Bluffs2
Albany1
Buffalo1
Campos dos Goytacazes1
Curitiba1
Fort Worth1
Guarapuava1
Guayaquil1
Lansdowne1